Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2025
EU-HTA: maintaining the achievements of AMNOG
20 January 2025 - IQWiG welcomes the fact that the adjustments to the AMNOG procedure planned for the integration with European ...
Posted by Michael Wonder on 16 Dec 2024
Findings from the EUnetHTA 21 project for EU-HTA from 2025
12 December 2024 - The results from EUnetHTA 21 provide insights for future cooperation in EU-HTA: participants from IQWiG and ...
Posted by Michael Wonder on 09 Aug 2024
BioMarin announces updated strategy for Roctavian to focus on US, Germany and Italy
5 August 2024 - Strategic focus will reduce operating expenses with the goal of achieving Roctavian profitability by end of 2025. ...
Posted by Michael Wonder on 04 Aug 2024
How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe
1 August 2024 - This paper elicited the opinions of European stakeholders on how HTA can be improved to facilitate access. ...
Posted by Michael Wonder on 13 Jun 2024
Comparing new medicine availability across Europe
12 June 2024 - Each year, the European Pharmaceutical Industry Association (EFPIA) publishes data comparing the availability of new medicines across ...
Posted by Michael Wonder on 17 Aug 2023
Do France, Germany, and Italy agree on the added therapeutic value of medicines?
17 August 2023 - The Health Technology Assessment of medicines is performed separately at the country level with some differences, but ...
Posted by Michael Wonder on 27 Jul 2023
Access and availability: Why are Europeans finding it hard to get the new medicines they need?
27 July 2023 - Patients are struggling to get hold of the new medicines they desperately need and ask what ...
Posted by Michael Wonder on 03 Jul 2023
EU-HTA: G-BA coordinates parallel scientific consultations for manufacturers from September
3 July 2023 - From 2025, a systematic evaluation of clinical studies for new medicinal products and medical devices will ...
Posted by Michael Wonder on 13 Jun 2023
Planned revision of EU pharmaceutical legislation: early market access and robust evidence need not remain a contradiction in terms
13 June 2023 - On 26 April, the EU Commission presented a proposal for the revision of pharmaceutical legislation in ...
Posted by Michael Wonder on 13 Apr 2023
Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement
11 April 2023 - The aims of this study were to review the current interactions within and across regulatory and HTA ...
Posted by Michael Wonder on 07 Feb 2023
The EU butts heads with big pharma to make medicines cheaper
2 February 2023 - The bloc’s pharma reform aims to get new drugs to patients faster, for less money. But it ...
Posted by Michael Wonder on 19 Jan 2023
The battle over European drug pricing
19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...
Posted by Michael Wonder on 17 Jan 2023
Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe
16 January 2023 - Bayer has said it is shifting the focus of its pharmaceutical business to the US and ...
Posted by Michael Wonder on 07 Dec 2022
Differences in evidentiary requirements between European Medicines Agency and European health technology assessment of oncology drugs—can alignment be enhanced?
5 December 2022 - National health technology assessments across Europe show differences in evidentiary requirements from assessments by the EMA, affecting ...
Posted by Michael Wonder on 23 Aug 2022
The EU HTA regulation: a new frontier for access to innovative technologies
23 August 2022 - A new health technology regulation is due to be applied to help EU countries determine the effectiveness ...